Lyrica Cr Tablet, Film Coated, Extended Release
Product Images NDC 58151-245

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lyrica Cr (NDC 58151-245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lyrica Cr Er Tablets 165 mg Bottle Label (Lyrica Cr Er Tablets 165 mg Bottle Label)

Label for Lyrica CR 165 mg extended release tablets containing pregabalin, for oral use. The label specifies storage instructions, dosage information, and includes a barcode. It states the package contains 30 film-coated tablets and is Rx only. The labeler is Viatris Specialty LLC.*

FDA Label Image

Lyrica Cr Er Tablets 330 mg Bottle Label (Lyrica Cr Er Tablets 330 mg Bottle Label)

Label for Lyrica CR (pregabalin) extended release tablets with a strength of 330 mg. The label indicates the product contains 30 film-coated tablets, is for oral use, and is prescription-only. Storage instructions specify temperatures between 20°C and 25°C with permitted excursions. Labeler is Viatris Specialty LLC.*

FDA Label Image

Lyrica Cr Er Tablets 82.5 mg Bottle Label (Lyrica Cr Er Tablets 82.5 mg Bottle Label)

Label for Lyrica CR (pregabalin) extended release tablets, 82.5 mg strength. The label indicates storage instructions at 20°C to 25°C, dispensing in child-resistant containers, and a quantity of 30 tablets. The product is Rx only and includes a barcode. Labeler name is not visible on this image.*

FDA Label Image

Cockcroft And Gault Equation (Image 01)

A formula for estimating creatinine clearance (CLCr) is shown, involving age, weight, serum creatinine, and a factor for female patients. This text panel appears to be a pharmacokinetic calculation related to Lyrica CR (pregabalin) extended-release tablets.*

FDA Label Image

Chemical Structure Of Pregabalin (Image 02)

Chemical structure of pregabalin, showing the molecular arrangement including amine and carboxyl functional groups with its carbon backbone.*

FDA Label Image

Figure 1 (Image 03)

A line graph comparing the percent improvement in pain from baseline between Pregabalin and placebo groups. The x-axis represents percent improvement thresholds from greater than 0 to 100%, and the y-axis shows the percent of patients improved, ranging from 0 to 100%. Two curves depict patient improvement percentages for Pregabalin (solid line) and placebo (dashed line).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.